TORONTO, April 01, 2026 (GLOBE NEWSWIRE)-- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...
— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...
TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...
TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...
MRI-guided transurethral ultrasound ablation (TULSA) resulted in significantly faster recovery, less perioperative morbidity, and better early functional outcomes than robotic radical prostatectomy in ...
Good morning, everyone. I'm delighted that you have joined us today. Friday, March 13, is a wonderful day. As you know, TULSA is a treatment modality for prostate disease. And although it is a device, ...
Arun Menawat, CEO of Profound Medical, talks about the company’s innovative TULSA-PRO technology. In a recent interview, Arun Menawat, CEO of Profound Medical, discussed the company’s innovative TULSA ...
Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...
Bill Faulkner had long approached prostate cancer testing with skepticism. For almost a decade, the 73-year-old had avoided the prostate-specific antigen test because of concerns about over-diagnosis; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results